Psychiatr. praxi. 2024;25(1):32-36 [Neurol. praxi. 2023;24(6):464-468]

Long­‑term treatment for depression in neurologic diseases

prof. MUDr. Eva Češková, CSc.
Psychiatrická klinika LF MU a FN Brno
KPN LF Ostravská univerzita
Oddělení psychiatrie, FN Ostrava

Depression belongs to frequent comorbidities in neurological diseases. There are some common etiopathogenetic factors and depression negatively influences the course of neurologic disorders. Diagnostics and treatment of comorbid depression is usually carried out by neurologist, however, in the case of severe and/ or unsuccessful treated depression psychiatric consultation is necessary. The paper deals in more details with pharmacotherapy for chosen long-term neurological disorders and is focused on the newest information and specifics in individual diseases.

Keywords: stroke, multiple sclerosis, chronic pain, epilepsy, migraine, Parkinson's disease, comorbid depression, pharmacotherapy.

Published: March 28, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Češková E. Long­‑term treatment for depression in neurologic diseases. Psychiatr. praxi. 2024;25(1):32-36.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Aggarwal M, Veena Puri V, Puri S. Serotonin and CGRP in migraine. Ann Neurosci. 2012;19(2):88-94. Go to original source... Go to PubMed...
    2. Bomasang­‑Layno E, Fadlon I, Murray AN, Himelhoch S. Antidepressive treatments for Parkinson's disease: a systematic review and meta­‑analysis. Parkinsonism Relat Disord. 2015;21:833-842. Go to original source... Go to PubMed...
    3. Češková E. Jak správně zvolit antidepresivum. Psychiat. praxi. 2007;8(5):229-231.
    4. Češková E. Současnost a budoucnost farmakoterapie závažných psychických poruch. Čas. Lék. čes. 2018;157:96-100.
    5. Daňsová, P, Masopustová Z, Hanáčková V, et al. Metoda Patient Health Questionnaire-9: česká verze. Československá psychologie. 2016;60(5):468-481.
    6. Epps SA. Commonalities for comorbidity: Overlapping features of the endocannabinoid system in depression and epilepsy. Front Psychiatry. 2022;13:1041460. doi: 10.3389/fpsyt.2022.1041460. Go to original source... Go to PubMed...
    7. Grundmann M, Kacířová I. Farmakokinetické a farmakodynamické lékové interakce antiepileptik. Klin Farmakol Farm. 2021;35(1):12-18. Go to original source...
    8. Chikatimalla R, Dasaradhan T, Koneti J, et al. Depression in Parkinson's disease: a narrative review. Cureus. 2022;14(8):e27750. Go to original source... Go to PubMed...
    9. Kotas R. Migréna - od patofyziologie k monoklonálním protilátkám. Neurol. praxi. 2019;20(4):296-300. Go to original source...
    10. Maguire MJ, Marson AG, Nevitt SJ. Antidepressants for people with epilepsy and depression. Cochrane Database Syst Rev. 2021;4(4):CD010682. Go to original source... Go to PubMed...
    11. Machado M, Iskedjian M, Ruiz I, Einarson TR. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta­‑analysis of head­‑to­‑head trials. Curr Med Res Opin. 2006;22(9):1825-37. Go to original source... Go to PubMed...
    12. McIntosh GE, Liu ES, Allan M, et al. Clinical practice guidelines for the detection and treatment of depression in multiple sclerosis: a systematic review. Neurol Clin Pract. 2023;13(3):e200154. Go to original source... Go to PubMed...
    13. Nežádal T. Co je nového v terapii migrény? Klin Farmakol Farm. 2022;36(4):123-128. Go to original source...
    14. Orzelska­‑Górka J, Mikulska J, Wiszniewska A, et al. New Atypical antipsychotics in the treatment of schizophrenia and depression. Int J Mol Sci. 2022;23(18):10624. Go to original source... Go to PubMed...
    15. Patten SB, Marrie RA, Carta MG. Depression in multiple sclerosis. Int Rev Psychiat. 2017;29(5):463-472. Go to original source... Go to PubMed...
    16. Pisani F, Pisani LR, Barbieri MA, et al. Optimization of therapy in patients with epilepsy and psychiatric comorbidities: Key points. Curr Neuropharmacol. 2023;21(8):1755-1766. Go to original source... Go to PubMed...
    17. Racková S. Deprese u neurologických onemocnění: výskyt a její léčba. Neurol. praxi. 2018;19(3):213-217. Go to original source...
    18. Robinson RG, Jorge RE, Starkstein SE. Poststroke depression: An update. J Neuropsychiatry Clin Neurosci. 2023, doi: 10.1176/appi.neuropsych.21090231. Go to original source... Go to PubMed...
    19. Scholz J, Finnerup NB, Attal N, et al. Classification Committee of the Neuropathic Pain Special Interest Group (Neu­PSIG), and Task Force for the Classification of Chronic Pain of the International Association for the Study of Pain (IASP). Pain. 2019;160(1):53-59. Go to original source... Go to PubMed...
    20. Solaro C, Gamberini G, Masuccio FG. Depression in multiple sclerosis: Epidemiology, aetiology, diagnosis and treatment. CNS Drug. 2018;32(2):117-133. Go to original source... Go to PubMed...
    21. Suchopár J, Suchopár Š, Prokeš M. Lékové interakce antimigrenik (2. část). Remedia. 2021;31:391-397.
    22. Štětkářová I, Horáček J. Deprese u vybraných neurologických onemocnění. Cesk Slov Neurol. 2016;79/112(6):626-638. Go to original source...
    23. Tay J, EFFECTS Trial Collaboration, Mårtensson B, et al. Does fluoxetine reduce apathetic and depressive symptoms after stroke? An analysis of the efficacy of fluoxetine­‑a randomized controlled trial in stroke trial data set. Int J Stroke. 2023;18(3):285-295. Go to original source... Go to PubMed...
    24. Vondráčková D. Chronická bolest - patofyziologie a léčba. Neurol. praxi. 2004;6:337-343.
    25. Wang H. MicroRNAs, Multiple sclerosis, and depression. Int J Mol Sci. 2021;22(15):7802. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.